Kara Klinkebiel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kara Klinkebiel has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Angela C. Onorato
The Heart Center (A.O., I.K., K.T., V.G., M.L.M.), The Ohio State University College of Medicine, Columbus, OH
1 shared publication - Bimal Pankaj Chaudhari
The Steve and Cindy Rasmussen Institute for Genomic Medicine, The Abigail Wexner Research Institute, Nationwide Children's Hospital Columbus Ohio USA
1 shared publication - Isaac Kistler
Statistics and Biostatistics Analyst II, Center for Biostatistics, Department of Biomedical Informatics, Nationwide Children’s Hospital, Columbus, USA
1 shared publication - Karen Texter
The Heart Center, Nationwide Children’s Hospital
1 shared publication - Kathryn Vannatta
Nationwide Children’s Hospital and Ohio State University Columbus Ohio USA
1 shared publication - May Ling Mah
The Heart Center (A.O., I.K., K.T., V.G., M.L.M.), The Ohio State University College of Medicine, Columbus, OH
1 shared publication
Latest Publications
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e005527
Assessing Genetic Testing in Adult Congenital Heart Disease: Current State and Patient Perspectives
BACKGROUND: Genetic variation affects clinical outcomes, prognosis, and family planning decisions in individuals with congenital heart disease (CHD). While genetic testing recommendations for infants and children with CHD have expanded, similar broad guidelines are lacking for patients with adult CHD (ACHD). Here, we investigated the current state of genetic testing in patients with ACHD and their perceptions toward testing, which has not been previously reported. METHODS: A single-center prospective cohort survey of patients with ACHD aged ≥18 years was evaluated in a large ACHD clinic over a 12-month period. RESULTS: Among 336 survey respondents (median age, 29 years; 52% male), CHD lesions were wide ranging, albeit largely represented by conotruncal (35%) or left ventricular outflow tract (35%) lesions. Most patients did not have children (64%) or a family history of CHD (79%). Thirteen percent had evidence of prior genetic testing despite 41% to 98% meeting criteria by current pediatric recommendations. Most desired genetic testing (68%) though interest varied by sex, education level, and family status. Individual and family health factors were reported as the most influential considerations for genetic testing. CONCLUSIONS: Few patients with ACHD have had genetic testing despite most being eligible based on current pediatric guidelines, likely related to birth era. Patients were interested in genetic testing though demographic factors and family status affected interest. The lack of broad recommendations for genetic testing in the ACHD population likely represents a significant barrier to increased utilization of genetic tests.
- 1 April 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (2) , e005527
Assessing Genetic Testing in Adult Congenital Heart Disease: Current State and Patient Perspectives
BACKGROUND: Genetic variation affects clinical outcomes, prognosis, and family planning decisions in individuals with congenital heart disease (CHD). While genetic testing recommendations for infants and children with CHD have expanded, similar broad guidelines are lacking for patients with adult CHD (ACHD). Here, we investigated the current state of genetic testing in patients with ACHD and their perceptions toward testing, which has not been previously reported. METHODS: A single-center prospective cohort survey of patients with ACHD aged ≥18 years was evaluated in a large ACHD clinic over a 12-month period. RESULTS: Among 336 survey respondents (median age, 29 years; 52% male), CHD lesions were wide ranging, albeit largely represented by conotruncal (35%) or left ventricular outflow tract (35%) lesions. Most patients did not have children (64%) or a family history of CHD (79%). Thirteen percent had evidence of prior genetic testing despite 41% to 98% meeting criteria by current pediatric recommendations. Most desired genetic testing (68%) though interest varied by sex, education level, and family status. Individual and family health factors were reported as the most influential considerations for genetic testing. CONCLUSIONS: Few patients with ACHD have had genetic testing despite most being eligible based on current pediatric guidelines, likely related to birth era. Patients were interested in genetic testing though demographic factors and family status affected interest. The lack of broad recommendations for genetic testing in the ACHD population likely represents a significant barrier to increased utilization of genetic tests.